Trazodone generates m-CPP: in 2008 risks from m-CPP might outweigh benefits of trazodone.
Author(s): Kast RE
Affiliation(s): Department of Psychiatry, University of Vermont, Burlington, VT 05401, USA. rekast@email.com
Publication date & source: 2009, World J Biol Psychiatry., 10(4 Pt 2):682-5.
Since deleterious effects of m-CPP, the primary catabolic metabolite of trazodone, were last reviewed 2 years ago, research data continue to accrue showing that clinically significant levels of m-CPP (a) are generated in patients using trazodone for sleep and (b) are present 24 h a day and (c) have potentially serious ill effects. This commentary argues that the documented potential for harm and multiple risks of m-CPP outweigh potential benefits of trazodone, given the development and marketing of many safer alternatives since trazodone's introduction in the 1980s.
|